Aptorum Group Limited.
APM.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Aptorum Group Limited is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. The company focuses on identifying, developing, and commercializing therapeutic candidates across a range of disease areas, including infectious diseases, g...Show More
Better Health for All
0
No specific, quantifiable evidence was found in the provided articles to assess Aptorum Group Limited against any of the 'Better Health for All' KPIs. The articles primarily consist of disclaimers, financial transaction details, and general statements about the company's aims and pipeline projects, without providing data on health outcomes, product safety, accessibility, R&D allocation percentages, or ethical practices in clinical trials or data management.
Fair Money & Economic Opportunity
0
Aptorum Group Limited is a pharmaceutical company.
1
Its core business activities do not involve lending, insuring, moving, or storing money for consumers, nor does it offer financial products or services that would directly impact financial inclusion or economic opportunity for marginalized populations. Therefore, all KPIs related to financial services, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its operations.
Fair Pay & Worker Respect
0
As of October 10, 2025, none of APM's employees are represented by a labor union or covered by a collective bargaining agreement.
1
In 2021, the worker engagement score was 64%, which decreased to 48% in 2022.
2
The company has 2 full-time employees and 5 independent contracted consultants and advisors.
3
For a specific Sr. Vice President and CFO, the employment is part-time and non-exclusive, allowing up to 60% of professional time for other ventures.
4
This individual is eligible for DiamiR group health insurance (including prescription benefits), dental and vision plans (with the company covering the employee's cost, but not dependents), and group life insurance.
5
The company will also match 401(k) contributions up to 4% for this employee.
6
Fair Trade & Ethical Sourcing
0
The provided articles, including a financial report summary and the company's audit committee charter, explicitly state that no information is available regarding Aptorum Group Limited's fair trade and ethical sourcing practices. Specifically, no data was found for fair-trade certification share, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clause coverage in supplier contracts, share of high-risk materials, or supplier diversity spend.
1
Honest & Fair Business
0
No specific, concrete data points were found in the provided articles for any of the KPIs under the 'Honest & Fair Business' value. While some articles mention the existence of an independent audit committee
1
, SEC filings
2
, and a Code of Business Conduct and Ethics
3
, they do not provide the quantitative metrics required by the rubric, such as a recognized transparency index score, total value of regulatory fines, percentage of board members free from conflicts, or average complaint resolution time. Therefore, all KPIs are omitted due to lack of direct evidence.
Kind to Animals
-70
Aptorum Group evaluates drug candidates using both cell-based and animal models, with animal models specifically used for validation.
1
While an AI platform (Smart-ACT) and computational screening of 1,615 drugs are used, non-animal assays cover early-stage screens but animal models are still used for validation.
2
The company conducts animal tests in areas such as gut microbiota research.
3
There is no explicit company-wide policy to prohibit or reduce animal testing, though one candidate drug, SACT-1, can be exempted from pre-clinical and animal testing.
4
The company uses 15,000–25,000 animals per year. Aptorum Group collaborates with the HKU team of microbiologists on non-antibiotic treatments but does not specify a commitment to animal-free standards or multi-stakeholder initiatives.
5
The company mentions the US FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) to expedite approval, but this is not an active engagement in animal welfare policy improvement.
6
No War, No Weapons
0
No data relevant to the 'No War, No Weapons' ethical value was found in the provided articles for Aptorum Group Limited. The articles explicitly state that they focus on the company's financial performance and overview as a pharmaceutical/life sciences company, with no information related to arms production, defense contracts, dual-use technology, or any other metrics pertinent to this value.
1
Planet-Friendly Business
0
No evidence available to assess Aptorum Group Limited on Planet-Friendly Business.
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to "Respect for Cultures & Communities." While one article mentioned "collaborative agreements with indigenous entities," it did not specify the number, which is required for scoring the relevant KPI.
1
The other articles contained financial information or general company descriptions without details on community engagement, cultural practices, or related metrics.
2
Safe & Smart Tech
0
No specific, concrete data points or factual information regarding Aptorum Group Limited's data protection, cybersecurity, or responsible AI practices were found in the provided articles. The articles primarily consist of legal disclaimers
1
, SEC filing information
2
, and financial results
3
, none of which address the KPIs related to Safe & Smart Tech. Some articles explicitly state the absence of such data.
4
Zero Waste & Sustainable Products
0
No specific, quantifiable evidence was found in the provided articles regarding Aptorum Group Limited's current performance across any of the 'Zero Waste & Sustainable Products' KPIs. The articles mention that the company's Hong Kong operations are subject to waste disposal regulations and that its labs must ensure compliance with EPA hazardous waste requirements by September 2025.
1
However, these are regulatory obligations or future requirements/recommendations, not concrete data points on current waste diversion rates, product recyclability, packaging sustainability, or any other specific waste management initiatives or outcomes for the company. Industry trends or requirements for other companies are not attributable to Aptorum Group Limited.